HIV/AIDS-related cardiovascular disease.
Recent advances in antiretroviral therapies have enhanced survival of HIV/AIDS patients, but cardiovascular complications have emerged as important issues in this growing patient population. Although the antiviral drug therapies apparently yield cardiac and/or vascular toxicities themselves, several other factors associated with HIV pathogenesis have also been implicated. This brief review provides an overview of the significance and complexities of HIV/ AIDS-related cardiovascular complications and addresses some important mechanistic aspects that may contribute to this important clinical problem.
Chaves
Alysia A
AA
Center for Cardiovascular Medicine, Columbus Children's Research Institute, Columbus, OH 43205, USA.
Mihm
Michael J
MJ
Basuray
Anupam
A
Baliga
Reshma
R
Ayers
Leona W
LW
Bauer
John A
JA
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D019966:Substance-Related Disorders / Q000150:complications; D014481:United States / Q000453:epidemiology
D019380:Anti-HIV Agents